Repositioning Candidate Details
| Candidate ID: | R1379 |
| Source ID: | DB11584 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Pipradrol |
| Synonyms: | Pipradrol |
| Molecular Formula: | C18H21NO |
| SMILES: | [H]N1CCCCC1C(O)(C1=CC=CC=C1)C1=CC=CC=C1 |
| Structure: |
|
| DrugBank Description: | Pipradrol (Meratran) was initially developed in the 1950s as an antidepressant, however, the adverse effects associated with its use and its abuse potential led to its withdrawal and international regulation . Pipradrol was made illegal in many countries in 1970s because of its potential for abuse. It is currently classified under the Misuse of Drugs Act as a Class C substance . Experimentation with the drug and its derivatives for recreational purposes has led to many cases of acute toxicity and has been linked to three fatalities. The social and in particular acute clinical harms of pipradrol derivatives have led to their control under the Misuse of Drugs Act 1971 in the UK in 2012 . Interestingly, this drug has been studied for bactericidal properties, however, is not currently, used for this purpose . In addition to this, it has shown favorable effects in postpartum depressive symptoms . |
| CAS Number: | 467-60-7 |
| Molecular Weight: | 267.372 |
| DrugBank Indication: | Used to manage fatigue and depression , , , . Used as an adjunct therapy in the management of obesity . |
| DrugBank Pharmacology: | Pipradrol (Meratran) is a psychoactive agent and a central nervous system stimulant that has proven useful in the field of psychiatry . Pipradrol was initially used as an adjunct in the dietary management of obesity as well as for the management of dementia symptoms. Numerous reports have been made on the properties of pipradrol, demonstrating its favorable effects in the treatment of depression and fatigue in addition to a variety of other conditions including narcolepsy, spasmodic torticollis, schizophrenia and in geriatric practice . |
| DrugBank MoA: | Pipradrol and pipradrol derivatives are norepinephrine and dopamine reuptake inhibitors . In a pharmacokinetic study, it was shown that pipradrol conditioned place preference (CPP) was blocked by selective D1 dopamine antagonist, implicating that a rewarding effect of pipradrol may involve the activation of D1 dopamine receptors. Pipradrol has a definite cerebral stimulating effect without affecting the blood pressure or respiration and has been used to counteract post-anaesthetic and chlorpromazine depression in man. Structurally related to phenylmethylamphetamine, a potent stimulant with a long half-life, pipradrol differs from amphetamine in that its action is more intense at higher centers, it does not exhibit pressor activity, there is no post-excitement depression, and this drug does not decrease appetite, as occurs with amphetamine . |
| Targets: | D(1) dopamine receptor agonist |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Diseases ID | DO ID | Disease Name | Definition | Class | |
|---|---|---|---|---|---|
| I17 | 1596 | Mental depression | Mental depression | disease of mental health/ cognitive disorder/ mood disorder | Details |
| I14 | 9970 | Obesity | An overnutrition that is characterized by excess body fat, traditionally defined as an elevated ratio of weight to height (specifically 30 kilograms per meter squared), has_material_basis_in a multifactorial etiology related to excess nutrition intake, decreased caloric utilization, and genetic susceptibility, and possibly medications and certain disorders of metabolism, endocrine function, and mental illness. https://en.wikipedia.org/wiki/Obesity | disease of metabolism/acquired metabolic disease/ nutrition disease/overnutrition | Details |